Background Systemic sclerosis (SSc) is characterized by widespread tissue fibrosis including the myocardium. Diffuse myocardial fibrosis can be detected non-invasively by extracellular volume (ECV) imaging based on pre-and postcontrast T1 measurements using cardiovascular magnetic resonance (CMR). We hypothesized that multiparametric CMR, including T1 mapping, can detect subclinical myocardial involvement and provide a comprehensive cardiac assessment in patients with SSc.
Methods
19 SSc patients (18 female, mean age 55 ± 10 years) and 20 controls (19 female, mean age 56 ± 8 years) without overt cardiovascular disease underwent CMR at 1.5T. CMR assessments included late gadolinium enhancement (LGE) [IV gadoterate meglumine at 0.15 mmol/kg], T1 mapping pre-and postcontrast, cine, tagging, and T2-weighted imaging.
Results
Focal fibrosis on LGE was found in 10 SSc patients (53%) but none of controls. Evidence of diffuse myocardial fibrosis in SSc patients was supported by significantly higher precontrast T1 values (1007 ± 29 vs. 958 ± 20 ms, p < 0.001) and expansion of ECV (35.4 ± 4.8 vs. 27.6 ± 2.5 %, p < 0.001). Regardless of any regional fibrosis, indices of diffuse myocardial fibrosis were significantly elevated in SSc and correlated with disease activity and severity. Although biventricular size and global function were preserved, peak systolic circumferential strain (-16.8 ± 1.6 vs. -18.6 ± 1.0, p < 0.001) and peak diastolic strain rate (83 ± 26 vs. 114 ± 16 s-1, p < 0.001) were impaired in SSc. Impaired myocardial systolic strain and diastolic strain rate inversely correlated with diffuse myocardial fibrosis indices. There was no evidence of myocardial edema in SSc.
Conclusions
Cardiac involvement is common in SSc even in the absence of cardiac symptoms, and includes both focal and ubiquitous diffuse myocardial fibrosis; this is associated with impaired systolic and diastolic strain parameters, as well as disease activity and severity. CMR may be useful in future in the study of treatments aimed at preventing or reducing diffuse myocardial fibrosis in SSc.
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